# Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis

> **NCT01445769** · PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 45 (actual)

## Conditions studied

- Primary Myelofibrosis
- Post-Polycythemia Vera Myelofibrosis
- Post-Essential Thrombocythemia Myelofibrosis

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT01445769
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-03
- **Final completion:** 2013-04
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2019-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01445769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01445769, "Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01445769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*